Drug Profile


Alternative Names: Champix; Chantix; CP-526,555; CP-526555-18; Varenicline tartrate

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class 3-ring heterocyclic compounds; Azabicyclo compounds; Benzazepines; Bridged-ring heterocyclic compounds; Quinoxalines; Small molecules; Smoking cessation therapies
  • Mechanism of Action Alpha4 beta2 nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Smoking withdrawal
  • Discontinued Alzheimer's disease

Most Recent Events

  • 01 Jan 2017 Pfizer completes a phase III trial in Smoking withdrawal in Pakistan (PO) (ISRCTN94103375)
  • 16 Dec 2016 US FDA approves removal of boxed warning regarding serious neuropsychiatric events from varenicline label
  • 31 Oct 2016 Pfizer completes the CATS extension study for Smoking cessation in USA, Argentina, Australia, Brazil, Bulgaria, Canada, Chile, Denmark, Finland, Germany, Mexico, New Zealand, Russia, Slovakia, South Africa and Spain (NCT01574703)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top